CASI Pharmaceuticals Q2 EPS $(0.52) Beats $(0.63) Estimate, Sales $3.98M Miss $4.43M Estimate
Portfolio Pulse from Benzinga Newsdesk
CASI Pharmaceuticals (NASDAQ:CASI) reported Q2 EPS of $(0.52), beating the $(0.63) estimate, but sales of $3.98M missed the $4.43M estimate. EPS improved by 32.47% YoY, while sales decreased by 59.48% YoY.
August 16, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
CASI Pharmaceuticals reported Q2 EPS of $(0.52), beating estimates by 17.46%, but sales of $3.98M missed estimates by 10.18%. EPS improved by 32.47% YoY, while sales decreased by 59.48% YoY.
The mixed results, with EPS beating estimates but sales missing, create a neutral short-term outlook. The significant YoY sales decline is concerning, but the EPS improvement is a positive sign.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100